Recent Advances in Nanoparticles-Based Platforms Targeting the PD-1/PD-L1 Pathway for Cancer Treatment

Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis showed remarkable improvements in overall response and patient survival, which changed the treatment landscape for multiple cancer types. However, the majority of patients receiving ICIs are either non-responders or eventually develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xin, Fang, Chao, Zhang, Kun, Su, Chunxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414242/
https://www.ncbi.nlm.nih.gov/pubmed/36015206
http://dx.doi.org/10.3390/pharmaceutics14081581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9414242/
https://www.ncbi.nlm.nih.gov/pubmed/36015206
http://dx.doi.org/10.3390/pharmaceutics14081581

Ejemplares similares